By Wendy Van Sickle
Columbus, Ohio, Oct. 31 – Credit Suisse AG, London Branch priced $503,000 of contingent coupon autocallable yield notes due Jan. 31, 2019 linked to the SPDR S&P Biotech exchange-traded fund, according to a 424B2 filing with the Securities and Exchange Commission.
Each quarter the notes will pay a contingent coupon at an annual rate of 8.5% if the fund closes at or above the coupon barrier, 70% of the initial level, for that quarter.
The notes will be called at par plus the contingent coupon if the fund closes at or above the initial level on any quarterly trigger observation date after six months.
The payout at maturity will be par unless the fund finishes below its initial level and ever closes below the knock-in level, 70% of the initial share price, in which case investors will lose 1% for each 1% decline in the fund from its initial level.
Credit Suisse Securities (USA) LLC is the agent.
| Issuer: | Credit Suisse AG, London Branch
|
| Issue: | Contingent coupon autocallable yield notes
|
| Underlying fund: | SPDR S&P Biotech ETF
|
| Amount: | $503,000
|
| Maturity: | Jan. 31, 2019
|
| Contingent payment: | 8.5% per year, payable quarterly if fund closes at or above coupon barrier level on observation date for that quarter
|
| Price: | Par
|
| Payout at maturity: | Par, unless share fund finishes below initial level and ever closes below knock-in level, in which case 1% loss for each 1% decline
|
| Call: | Automatically at par plus contingent payment if closing level is greater than or equal to initial level on any quarterly trigger observation date after six months
|
| Initial share level: | $81.81
|
| Coupon barrier/knock-in level: | $57.267, 70% of initial level
|
| Pricing date: | Oct. 26
|
| Settlement date: | Oct. 31
|
| Agents: | Credit Suisse Securities (USA) LLC
|
| Fees: | 2.5%
|
| Cusip: | 22550BJJ3
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
